About CMAB Biopharma
CMAB Biopharma is a company based in Suzhou (China) founded in 2017 was acquired by WuXi Biologics in March 2021.. CMAB Biopharma has raised $72 million across 2 funding rounds from investors including WuXi Biologics, Tigermed and CBC Group. CMAB Biopharma operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Suzhou, China
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$72 M (USD)
in 2 rounds
-
Latest Funding Round
$34 M (USD), Series B
Apr 02, 2018
-
Investors
WuXi Biologics
& 8 more
-
Employee Count
Employee Count
-
Acquired by
WuXi Biologics
(Mar 18, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CMAB Biopharma
CMAB Biopharma has successfully raised a total of $72M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in April 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $34.0M
-
First Round
First Round
(02 Jan 2018)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2018 | Amount | Series B - CMAB Biopharma | Valuation | CD Capital | |
| Jan, 2018 | Amount | Series A - CMAB Biopharma | Valuation | CBC Group , Biobay |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CMAB Biopharma
CMAB Biopharma has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include WuXi Biologics, Tigermed and CBC Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Venture capital, equity investment, and fund management services in China.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CMAB Biopharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CMAB Biopharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cmab Biopharma Comparisons
Competitors of CMAB Biopharma
CMAB Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cmab Biopharma
Frequently Asked Questions about CMAB Biopharma
When was CMAB Biopharma founded?
CMAB Biopharma was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is CMAB Biopharma located?
CMAB Biopharma is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
Is CMAB Biopharma a funded company?
CMAB Biopharma is a funded company, having raised a total of $72M across 2 funding rounds to date. The company's 1st funding round was a Series A of $38M, raised on Jan 02, 2018.
What does CMAB Biopharma do?
CMAB Biopharma was founded in 2017 and is based in Suzhou, China, where operations focus on the biopharmaceutical sector. Services are provided for biologics manufacturing, encompassing cell line development, upstream and downstream process optimization, formulation strategies, overall process and analytical method development, and stability assessments. These capabilities support pre-clinical and clinical-stage projects in a controlled environment.
Who are the top competitors of CMAB Biopharma?
CMAB Biopharma's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Who are CMAB Biopharma's investors?
CMAB Biopharma has 9 investors. Key investors include WuXi Biologics, Tigermed, CBC Group, Shenzhen Capital Group, and CD Capital.